Accessibility Menu
Camp4 Therapeutics Stock Quote

Camp4 Therapeutics (NASDAQ: CAMP)

$3.34
(4.7%)
+0.15
Price as of October 21, 2025, 3:48 p.m. ET

KEY DATA POINTS

Current Price
$3.41
Daily Change
(4.7%) +$0.15
Day's Range
$3.1 - $3.55
Previous Close
$3.41
Open
$3.18
Beta
1.48
Volume
109,787
Average Volume
785,382
Market Cap
68.7M
Market Cap / Employee
$3.41M
52wk Range
$1.31 - $12.26
Revenue
-
Gross Margin
0.44%
Dividend Yield
N/A
EPS
-$2.57
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Camp4 Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CAMP-68.72%N/AN/A-70%
S&P+15.06%+95.03%+14.29%+16%

Camp4 Therapeutics Company Info

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$1.50M0.0%
Gross Profit$1.07M0.0%
Gross Margin71.28%0.0%
Market Cap$29.23M0.0%
Market Cap / Employee$0.53M0.0%
Employees550.0%
Net Income-$12.59M0.0%
EBITDA-$12.60M0.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$39.05M0.0%
Accounts Receivable$1.00M0.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$3.95M0.0%
Short Term Debt$3.27M0.0%

Ratios

CurrentYOY Change
Return On Invested Capital-75.55%0.0%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$10.34M0.0%
Operating Free Cash Flow-$10.34M0.0%

Valuation

MetricQ4 2024Q1 2025Q2 2025YoY Change
Price to Book-0.661.280.57-
Price to Sales9.72-
Price to Tangible Book Value-0.661.280.57-
Enterprise Value to EBITDA-3.66-3.100.21-
Total Debt$9.64M$8.73M$7.96M$7.22M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.